Ly Vu

British Columbia Cancer Research Centre

Vancouver

Canada

SCHOLARLY PAPERS

1

DOWNLOADS

35

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (1)

1.

A Target Discovery Pipeline Identified ILT3 as a Target for Immunotherapy of Multiple Myeloma

Number of pages: 34 Posted: 23 Nov 2022
Indiana University Purdue University Indianapolis (IUPUI) - Indiana University School of Medicine, NGM Biopharmaceuticals, NGM Biopharmaceuticals, NGM Biopharmaceuticals, Indiana University Purdue University Indianapolis (IUPUI) - Indiana University School of Medicine, Indiana University Purdue University Indianapolis (IUPUI) - Indiana University School of Medicine, Indiana University Purdue University Indianapolis (IUPUI) - Indiana University School of Medicine, Indiana University Purdue University Indianapolis (IUPUI) - Indiana University School of Medicine, Indiana University Purdue University Indianapolis (IUPUI) - Indiana University School of Medicine, Indiana University Purdue University Indianapolis (IUPUI) - Indiana University School of Medicine, Columbia University - Proteomics and Macromolecular Crystallography Shared Resource, NGM Biopharmaceuticals, NGM Biopharmaceuticals, British Columbia Cancer Research Centre, Cornell University - Weill Cornell Medicine, Indiana University - Department of Medicine, Lonza Group AG, Indiana University Purdue University Indianapolis (IUPUI) - Indiana University School of Medicine, Indiana University - Department of Microbiology and Immunology and Indiana University Purdue University Indianapolis (IUPUI) - Indiana University School of Medicine
Downloads 35 (857,959)

Abstract:

Loading...

Mass-spectrometry, target discovery strategy, ILT3, Bivalent antibodies, T cells engager: Myeloma